[EN] N-HETEROARYLALKYL-2-(HETEROCYCLYL AND HETEROCYCLYLMETHYL) ACETAMIDE DERIVATIVES AS SSTR4 AGONISTS<br/>[FR] DÉRIVÉS DE N-HÉTÉROARYLALKYLE-2-(HÉTÉROCYCLYLE ET HÉTÉROCYCLYLMÉTHYLE) ACÉTAMIDE UTILISÉS EN TANT QU'AGONISTES DE SSTR4
申请人:TAKEDA PHARMACEUTICALS CO
公开号:WO2021202781A1
公开(公告)日:2021-10-07
Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein L, n, R1, R2, R6, R7, R8, R9, R10, X3, X4 and X5 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating diseases, disorders, and conditions associated with SSTR4.
Multivalent Peptidomimetic Conjugates: A Versatile Platform for Modulating Androgen Receptor Activity
作者:Paul M. Levine、Keren Imberg、Michael J. Garabedian、Kent Kirshenbaum
DOI:10.1021/ja300170n
日期:2012.4.25
We introduce a family of multivalent peptidomimetic conjugates that modulate the activity of the androgen receptor (AR). Bioactive ethisterone ligands were conjugated to a set of sequence-specific peptoid oligomers. Certain multivalent peptoid conjugates enhance AR-mediated transcriptional activation. We identify a linear and a cyclic conjugate that exhibit potent anti-proliferative activity in LNCaP-abl
我们介绍了一系列可调节雄激素受体 (AR) 活性的多价肽模拟物偶联物。生物活性乙甾酮配体与一组序列特异性拟肽寡聚体结合。某些多价拟肽缀合物增强 AR 介导的转录激活。我们鉴定了在 LNCaP-abl 细胞(一种抗治疗前列腺癌模型)中表现出有效抗增殖活性的线性和环状缀合物。线性偶联物通过竞争配体结合来阻断 AR 作用。相比之下,尽管环状缀合物在体外无法与内源性配体竞争与 AR 的结合,但它仍具有活性,这表明它是一种非竞争性作用模式。这些结果建立了一个多功能平台来设计具有潜在治疗意义的竞争性和非竞争性 AR 调节剂。